sick sinus syndrome
Conditions
Interventions
Study Group 1:Lingbao Huxin Pill for 4 weeks, discontinued for 2 weeks, placebo for 4 weeks
Study Group 2:Placebo for 4 weeks, discontinued for 2 weeks, Lingbao Huxin Pill for 4 weeks
Sponsors
Zhejiang Provincial Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.18-80 years old, male or female; 2.Implantation of a pacemaker with a recording function; 3.Have not undergone cardiac surgery within six months; 4.No serious cardiac dysfunction (cardiac function grade III.~IV., NYHA grade); 5.Traditional Chinese medicine distinguishes as qi deficiency and blood stasis; 6.Subject consents and signs informed consent form, and has the ability to comply with the study step, requires a third-party witness to co-sign when neither subject nor legal guardian can read and understand informed consent.
Exclusion criteria
Exclusion criteria: 1.Patients with severe primary diseases such as liver, kidney, hematopoietic system, and psychosis; 2.Abnormal liver function: patients with alanine aminotransferase ALT, aspartate aminotransferase AST > 2 times the upper limit of normal, or total bilirubin > upper limit of normal; 3.Abnormal renal function: patients with creatinine exceeding the upper limit of normal, or creatinine clearance CrCl < 50 mL/min (Cockcroft-Gault formula); 4.Female subjects of childbearing age who were pregnant, lactating, or planning to conceive or breastfeed during the study and did not use effective contraception; 5.Participate in other clinical trials within 3 months before participating in this study; 6.Patients who are not suitable for participation in clinical trials in the opinion of the investigators, including those who currently have physical or psychological conditions that prevent them from adhering to the protocol; 7.Those who are allergic to the test drug or its ingredients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pacemaker programmed parameters; | — |
Secondary
| Measure | Time frame |
|---|---|
| Dynamic electrocardiogram;Left atrial anteroposterior diameter;Left ventricular end-diastolic diameter;Left wall wall end-diastolic septal thickness;Thickness of the posterior wall of the left ventricle;Left ventricular ejection fraction;Grading of cardiac function; | — |
Countries
China
Contacts
Public ContactShuwei Huang
Zhejiang Provincial Hospital of Traditional Chinese Medicine
Outcome results
None listed